IBRN Fact Sheet: iShares Neuroscience and Healthcare ETF
Share
$31.67
close, Nov 20, 2026
Over the year to Nov 19, 2026, IBRN returned +11.4% in total and charged 0.47% a year.
- 1-year total return
- +10.0%
- to Nov 20, 2026
- Expense ratio
- 0.47%
- a year
- Net assets
- $8.1m
- on Nov 19, 2026
- Net flow, last 5 trading days
- $0
- daily basis to Nov 19, 2026
Growth of $10,000, 1 year
IBRN $11,142 +11.4% · ACWI $10,902 +9.0% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month+0.5%
3 months−20.1%
Year to date−2.0%
1 year+10.0%
3 years+53.7%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
BIOGEN5.42%
NEUROCRINE BIOSCIENCES5.05%
EDGEWISE THERAPEUTICS5.00%
Alkermes Public Limited Company4.78%
PRAXIS PRECISION MEDICINES4.37%
ARGENX SE ADR4.35%
AXOGEN4.34%
PTC THERAPEUTICS4.32%
DIANTHUS THERAPEUTICS3.97%
SK BIOPHARMACEUTICALS LTD3.82%
IBRN top ten by weight, 45.4% of the fund, of its 67 equity positions, from the holdings published by its issuer for Nov 13, 2026.
Facts
Holds 67 stocks in therapeutics and medical devices, 5% of its weight in S&P 500 companies · First traded Aug 26, 2022 · Benchmark Its own holdings, as of Nov 13, 2026